Cymabay Therapeutics Inc

+0.03 (+0.42%)
Regulatory, Earnings Announcements

Cymabay Therapeutics Reports Presentation Of Positive Results From Study Evaluating Seladelpar

Published: 11/16/2020 22:32 GMT
CymaBay Therapeutics Inc (CBAY) - Cymabay Therapeutics Announces Oral Late-breaking Presentation of Positive Results From the Enhance Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at the Liver Meeting® 2020.
Cymabay Therapeutics Inc - Results Highlight Potential for Seladelpar to Offer Patients an Efficacious and Safe Second Line Treatment Option.
Cymabay Therapeutics Inc - Global 52-week Phase 3 Registration Study (response) to Begin Enrolling Patients in Q1 of 2021.
Cymabay Therapeutics Inc - Seladelpar Demonstrated Anti-cholestatic, Anti-inflammatory, and Anti-pruritic Activity Through 3 and 6 Months.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.